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Over the course of the 20th century, health in China has advanced significantly. Nevertheless, 
China still faces many challenges in providing universal, high quality, affordable healthcare to its 
people. The China Medical Board (美国中华医学基金会, CMB) is dedicated to supporting solutions to 
these challenges as part of its broader mission of promoting health in China and other Asian 
countries. In strengthening Chinese capacities in health policy and systems sciences (HPS) research 
and health professional education (HPE), the CMB supports China’s ongoing health reforms by 
encouraging the expansion of China’s evidence-base for health policymaking. 
Under the HPS umbrella strategy, CMB Open Competition (CMB-OC) research is designed to 
nurture individual capacity especially for junior researchers from eligible institutions and 
encourages multidisciplinary approaches. The program’s strenuous merit-based peer review 
process seeks to identify excellent researchers or researchers with high potential, regardless of 
seniority. CMB-OC awards research funding of 25,000 USD - 150,000 USD per project for 2-5 years 
and, and entitles awardees opportunities for future collaborative learning, training, and 
mentorship. The CMB-OC program has run for three consecutive years since 2011 and has 
awarded 20 grants with funding ranging from 57,000 USD to 150,000 USD. The program is highly 
competitive. For instance, in the 2012 cycle, CMB received 123 project applications, of which 29 
abstracts were invited for full proposal development. Ultimately, 8 projects were approved for 
funding. 
The CMB-OC supports projects in the following broad areas of HPS. As a central theme, in 2013 
CMB-OC will prioritize equity in health and give special attention to the research that illuminates 
the measurement, causes, conditions, strategies and interventions to inequity in health.   
 Emerging health challenges in China, especially research involving diseases with a high 
burden of disease in China (but excluding wet-lab based research); and 
 Health policies and health systems responses to address emerging health challenges, 
such as those related to health governance, ethics, financing, human resources, care 
delivery systems, health technology assessment, pharmaceutical policies, and health 
informatics. 
  
